{"transactions":[{"id":4714,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T21:00:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":94200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant."}],"balance_after":94200,"derivative":{"exercise_price":1,"expiration_date":"2036-09-02","underlying":"Common Stock","underlying_shares":94200},"source":{"system":"sec-edgar","filing":"0001213900-26-097745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636168/000121390026097745/ownership.xml","form_type":"4"}},{"id":4713,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T21:00:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":62800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant."}],"balance_after":63300,"source":{"system":"sec-edgar","filing":"0001213900-26-097745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636168/000121390026097745/ownership.xml","form_type":"4"}},{"id":974103,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:27:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.32,"underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001636168-25-000003","document":"form4-12102025_061228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000163616825000003/form4-12102025_061228.xml","form_type":"4"}},{"id":974102,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:27:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.32,"underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001636168-25-000003","document":"form4-12102025_061228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000163616825000003/form4-12102025_061228.xml","form_type":"4"}},{"id":974101,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:27:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.31,"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001636168-25-000003","document":"form4-12102025_061228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000163616825000003/form4-12102025_061228.xml","form_type":"4"}},{"id":1104682,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:22:31.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10450,"derivative":{"exercise_price":2.32,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001415889-25-017846","document":"form4-06202025_080627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000141588925017846/form4-06202025_080627.xml","form_type":"4"}},{"id":1182803,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":70311},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182802,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":72156},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182801,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":18351},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182800,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182799,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.96,"expiration_date":"2029-07-12","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182798,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":23.49,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182797,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":41.7,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1182796,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:21:48.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":59.7,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028228/ownership.xml","form_type":"4"}},{"id":1472859,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T16:49:31.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10520,"derivative":{"exercise_price":7.32,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001415889-24-017680","document":"form4-06202024_080627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000141588924017680/form4-06202024_080627.xml","form_type":"4"}},{"id":1697777,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-29T22:24:56.000Z","date":"2023-12-28","kind":"grant","planned":false,"acquired":true,"shares":70311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested."}],"balance_after":70311,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":70311},"source":{"system":"sec-edgar","filing":"0001213900-23-100091","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390023100091/ownership.xml","form_type":"4"}},{"id":1748443,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T19:54:40.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of November 3, 2023 (the \"Vesting Commencement Date\"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.9312,"expiration_date":"2033-11-02","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-23-054582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919123054582/doc4.xml","form_type":"4"}},{"id":2216799,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T23:17:37.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":72156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested."}],"balance_after":72156,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":72156},"source":{"system":"sec-edgar","filing":"0001213900-22-036875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022036875/ownership.xml","form_type":"4"}},{"id":2578641,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T21:00:50.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":18351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested."}],"balance_after":18351,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":18351},"source":{"system":"sec-edgar","filing":"0001213900-21-046679","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021046679/ownership.xml","form_type":"4"}},{"id":3057003,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-14T21:02:21.000Z","date":"2020-08-12","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested."}],"balance_after":8333,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001213900-20-022313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390020022313/ownership.xml","form_type":"4"}},{"id":3460570,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2019-07-16T20:55:38.000Z","date":"2019-07-12","kind":"grant","acquired":true,"shares":250000,"price":0.232,"value":58000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant."}],"balance_after":250000,"derivative":{"exercise_price":0.232,"expiration_date":"2029-07-12","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001213900-19-012869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390019012869/ownership.xml","form_type":"4"}},{"id":3866000,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2018-07-17T21:19:39.000Z","date":"2018-07-13","kind":"grant","acquired":true,"shares":75000,"price":0.7829,"value":58717.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":0.7829,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-18-009327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018009327/ownership.xml","form_type":"4"}},{"id":4382036,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10180,"kind":"person","name":"Nicholson, C. David","position":1,"cik":"0001636168","reported_name":"Nicholson, C. David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2017-03-16T20:33:59.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":75000,"price":1.39,"value":104250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":1.39,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-17-002465","document":"f4031417nicholson_actinium.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390017002465/f4031417nicholson_actinium.xml","form_type":"4"}}]}